The mRNA Cancer Vaccine Changing Melanoma's Odds

Five-year trial data show a personalised mRNA vaccine slashed melanoma recurrence by 49% alongside immunotherapy

3 Jun 2026

Melanoma still defeats nearly half its patients. Even after surgery, roughly half of high-risk cases come back within five years, a stubborn rate that has pushed researchers toward a new class of weapon: vaccines built from the patient's own tumor.

Five-year data from the KEYNOTE-942 trial, presented at the 2026 ASCO Annual Meeting and published simultaneously in the Journal of Clinical Oncology, confirm the results. Intismeran autogene paired with pembrolizumab reduced the risk of recurrence or death by 49% compared to immunotherapy alone. Among 157 patients with high-risk resected melanoma, nearly 70% who received the combination remained cancer-free at five years, against 49% in the standard group.

Each dose is built from scratch for the individual. The vaccine encodes up to 34 tumor-derived neoantigens, protein markers unique to that person's cancer, identified through next-generation DNA sequencing. Moderna and Merck designed it to work alongside pembrolizumab's checkpoint inhibition, generating a targeted immune attack while stripping away the signal tumors use to hide.

Significant challenges remain. KEYNOTE-942 enrolled patients only across Australian and US sites, limiting how broadly its findings apply, and the sample size falls short of what regulators need. Manufacturing a bespoke dose for each patient, spanning biopsy, sequencing, and custom synthesis before post-surgical windows close, poses a serious logistics problem.

Phase 3 answers may come soon. INTerpath-001, enrolling 1,000 patients globally including European sites, is testing intismeran as frontline adjuvant therapy in melanoma, with interim results expected before the end of 2026. A companion trial extends the hypothesis to lung cancer, and regulatory submissions to the EMA and FDA could follow within two years of a strong readout. For the broader mRNA sector, the direction is clear: validated personalised cancer vaccines would drive demand for sequencing infrastructure and manufacturing capacity across multiple continents, building on foundations laid during the pandemic.